GCCL and OPIS forge global clinical trial alliance
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
GCCL aims to leverage the partnership to expand strategic relationships with global CROs
The updated closure system introduces intuitive handling, innovative functionality and a premium design compatible with a wide range of syringe formats
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
The proceeds from the ?IP will be primarily utilized to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Limited
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products
The acquisition of AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) positions Bayer at the forefront of cardiac amyloidosis diagnostics
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
Subscribe To Our Newsletter & Stay Updated